1. Home
  2. VMD vs ALLO Comparison

VMD vs ALLO Comparison

Compare VMD & ALLO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Viemed Healthcare Inc.

VMD

Viemed Healthcare Inc.

HOLD

Current Price

$7.34

Market Cap

277.5M

Sector

N/A

ML Signal

HOLD

Logo Allogene Therapeutics Inc.

ALLO

Allogene Therapeutics Inc.

HOLD

Current Price

$1.39

Market Cap

252.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
VMD
ALLO
Founded
2006
2017
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
277.5M
252.9M
IPO Year
N/A
2018

Fundamental Metrics

Financial Performance
Metric
VMD
ALLO
Price
$7.34
$1.39
Analyst Decision
Buy
Analyst Count
0
11
Target Price
N/A
$8.67
AVG Volume (30 Days)
147.9K
2.5M
Earning Date
11-05-2025
11-06-2025
Dividend Yield
N/A
N/A
EPS Growth
35.92
N/A
EPS
0.34
N/A
Revenue
$254,794,000.00
N/A
Revenue This Year
$20.05
N/A
Revenue Next Year
$17.44
$100.00
P/E Ratio
$21.49
N/A
Revenue Growth
18.89
N/A
52 Week Low
$5.93
$0.86
52 Week High
$8.62
$3.78

Technical Indicators

Market Signals
Indicator
VMD
ALLO
Relative Strength Index (RSI) 59.78 49.50
Support Level $7.24 $1.32
Resistance Level $7.36 $1.52
Average True Range (ATR) 0.20 0.10
MACD 0.00 -0.02
Stochastic Oscillator 63.10 28.57

Price Performance

Historical Comparison
VMD
ALLO

About VMD Viemed Healthcare Inc.

Viemed Healthcare Inc is a provider of medical equipment and home therapy to patients with respiratory disease, oxygen problems, sleep apnea and PAP treatment. The company also provides services such as respiratory disease management, neuromuscular care, in-home sleep testing and sleep apnea treatment, oxygen therapy, respiratory equipment rentals, and healthcare staffing services. The company generates majority its revenue from medical equipment rental, sales and supply.

About ALLO Allogene Therapeutics Inc.

Allogene Therapeutics Inc is a clinical-stage biotech firm specializing in immuno-oncology, focusing on the development of genetically engineered allogeneic T-cell products for cancer and autoimmune diseases. Their pipeline includes off-the-shelf T-cell candidates designed to target cancer cells or autoreactive cells in autoimmune disorders. Notably, their allogeneic approach, derived from healthy donors, allows for broader patient eligibility and scalability. With a vision to redefine CAR T therapy, the company concentrates on core programs targeting lymphoma, leukemia, autoimmune diseases, and solid tumors. Revenue, generated from collaborations and licensing agreements, supports their research and development efforts.

Share on Social Networks: